Skincare products company Iberia Pharmaceuticals has announced its new hi-tech manufacturing and research facility spread across 60000 sq. ft. in Jhajjar, Haryana. The next-generation unit is expected to be operational by mid of 2026. The facility is designed to serve customers with science-baked, derma-driven, wellness products. The company has made a massive investment of ₹70 crore and is proud to be a part of the government backed ‘Make-in-India’ movement.
This unit is equipped with best-in-class control systems and equipment. The facility will be supported by an experienced team that will be committed to ensuring large-scale commercial manufacturing is carried on smoothly. The scale of manufacturing will not compromise on international standards of quality control. The plant will focus on delivering economically viable solutions, in a robust, compliant, and environmentally sustainable manner. The idea is to support customers who are seeking highly effective, and personalised skin-care products. Overall, with a focus on research and development, the high-tech research laboratories will support continuous tracking of market, consumer demand, product development, and judicious formulation improvement, all of which will be grounded in real-world science.
The new facility is complementary to Iberia’s current discovery capabilities and infrastructure, including clinical-grade treatments, which primarily focuses on nanotechnology-driven skincare solutions, and therapeutic solutions with a strong pharmaceutical backbone. The products are vegan, and built for high-performance skincare, across diverse categories.
Nitin Jain, Founder, Iberia Pharmaceuticals said, “By bringing global manufacturing quality to India, we are building trust, capacity, and a future where healthcare is held to a higher standard. This new plant marks a major milestone in our growth journey and will be fully compliant with global regulatory standards. The opening of this facility is one of multiple strategic initiatives that Iberia is implementing to support rapid growth. It also shows our firm commitment to the continued expansion of our business, building on years of proven experience and will enable us to serve our global customers efficiently. We fully support the Government of India in their efforts to increase access to high quality and affordable world-class products to improve healthcare, and we are very excited to begin work at our new manufacturing facility.”
At full scale, this manufacturing unit will make more than 12 million units a year in the areas of dermatology, wellness and chronic care for the Indian and global markets. The company will also generate over 600 jobs in this facility.
“Iberia believes in delving deep into research of science-backed skincare, leverages cutting edge nanotechnology to bring products that are pushing the boundaries of innovation and setting new benchmarks in dermatological excellence, expanding steadily into wellness and chronic care. At Iberia Pharmaceuticals, our purpose is clear, we want to deliver healthcare solutions that are precise, safe, and responsible. Our new, advanced manufacturing and research facility stands as a symbol of that commitment,” said Saurav Ojha, Co-Founder, Iberia Pharmaceuticals.
Iberia Pharmaceuticals also brings clinically tested, globally trusted brands to Indian consumers, including Sesderma, Mediderma, Dermpix, Noreva, Metacare amongst other respected brands. The audience includes not only individuals seeking better skin health, but also healthcare professionals, and clinics through a carefully created product portfolio.
